search
Back to results

Irrisept Trauma Study

Primary Purpose

Gustilo-Anderson Type III Open Tibia Fracture

Status
Recruiting
Phase
Phase 4
Locations
United States
Study Type
Interventional
Intervention
Irrisept (Irrigation Solution)
Saline
Sponsored by
Brett Crist
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Gustilo-Anderson Type III Open Tibia Fracture

Eligibility Criteria

18 Years - undefined (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

  1. Adult, 18 or over
  2. Gustilo-Anderson type III open tibia fracture
  3. Able to obtain informed consent from patient

Exclusion Criteria:

  1. Minor, under 18
  2. Pregnancy
  3. Prisoner
  4. Allergic to chlorhexidine gluconate
  5. Allergic to vancomycin or tobramycin
  6. Patient's tibia is unable to accommodate the smallest antibiotic nail
  7. Unable to provide informed consent

Sites / Locations

  • University of Missouri Health SystemRecruiting

Arms of the Study

Arm 1

Arm 2

Arm 3

Arm 4

Arm Type

Active Comparator

Experimental

Experimental

Experimental

Arm Label

Standard operative debridement and spanning external fixator (reference/control group)

Spanning external fixator with Irrisept irrigation (treatment group 1)

Antibiotic-coated medullary nail with saline irrigation (treatment group 2)

Antibiotic-coated medullary nail with Irrisept irrigation (treatment group 3)

Arm Description

This is the standard of care management. Patient will go to the operating room (OR) first for irrigation and debridement with normal saline and external fixation. Will return to OR at a later date for definitive fixation.

Patient will go to the operating room (OR) first for irrigation and debridement with Irrisept (the experimental irrigation solution) and external fixation. Will return to OR at a later date for definitive fixation.

Patient will go to the operating room (OR) for treatment with an antibiotic-coated nail and have irrigation and debridement with normal saline.

Patient will go to the operating room (OR) for treatment with an antibiotic-coated nail and have irrigation and debridement with Irrisept (the experimental irrigation solution).

Outcomes

Primary Outcome Measures

Rate of Surgical site infection (SSI)
Rate of surgical site infection (SSI) and wound complications following surgery. Measured by the number of surgical site infections in the total population of patients in the cohort. Deep infection indicates return to the operating room. Superficial infection indicates local wound care and oral antibiotics.

Secondary Outcome Measures

Fracture Healing
Presence or absence of fracture callous measured on x-ray by an experienced orthopaedic surgeon

Full Information

First Posted
April 5, 2022
Last Updated
November 1, 2022
Sponsor
Brett Crist
search

1. Study Identification

Unique Protocol Identification Number
NCT05402995
Brief Title
Irrisept Trauma Study
Official Title
Prospective Randomized Control Trial Comparing Temporary External Fixator to Antibiotic-coated IM Nail for Open Tibia Fractures
Study Type
Interventional

2. Study Status

Record Verification Date
November 2022
Overall Recruitment Status
Recruiting
Study Start Date
June 21, 2022 (Actual)
Primary Completion Date
April 5, 2024 (Anticipated)
Study Completion Date
April 5, 2024 (Anticipated)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor-Investigator
Name of the Sponsor
Brett Crist

4. Oversight

Studies a U.S. FDA-regulated Drug Product
Yes
Studies a U.S. FDA-regulated Device Product
No
Product Manufactured in and Exported from the U.S.
No
Data Monitoring Committee
No

5. Study Description

Brief Summary
Early debridement and definitive fixation, at the initial operative setting, historically led to no difference in the infection rates for Gustilo-Anderson type III open tibia fractures. However, Lenarz et al. reported that delaying definitive fixation in open tibia fractures could decrease the deep infection rate. At the University of Missouri, the investigators found that staged procedures, including initial debridement-temporary fixation and delayed definitive fixation, did not statistically decrease the rate of deep infection in Gustilo-Anderson type III fractures, prompting the study that is being proposed here. Antibiotic cement coated intramedullary nails have been used in management of infected long bone fractures. Since external fixation and staged debridement did not decrease type III open tibia infection rate, the investigators wanted to consider using antibiotic cement coated nails to deliver antibiotics locally in the acute open fracture setting to prophylactically decrease associated infection rate. Additionally, Irrisept is a wound irrigant that has been used to lower infection rates in different wound settings. To the investigators' knowledge, there are no robust data showing its effectiveness at lowering infection rates in open tibia fracture management. The purpose of this study is to determine the effects of Irrisept and antibiotic nails on lowering deep infection rates in type III open tibia fractures.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Gustilo-Anderson Type III Open Tibia Fracture

7. Study Design

Primary Purpose
Treatment
Study Phase
Phase 4
Interventional Study Model
Parallel Assignment
Model Description
Participants will be enrolled and randomized into one of four groups: Standard operative debridement and spanning external fixator (reference/control group) Spanning external fixator with Irrisept irrigation (treatment group 1) Antibiotic-coated medullary nail with saline irrigation (treatment group 2) or Antibiotic-coated medullary nail with Irrisept irrigation (treatment group 3)
Masking
None (Open Label)
Allocation
Randomized
Enrollment
230 (Anticipated)

8. Arms, Groups, and Interventions

Arm Title
Standard operative debridement and spanning external fixator (reference/control group)
Arm Type
Active Comparator
Arm Description
This is the standard of care management. Patient will go to the operating room (OR) first for irrigation and debridement with normal saline and external fixation. Will return to OR at a later date for definitive fixation.
Arm Title
Spanning external fixator with Irrisept irrigation (treatment group 1)
Arm Type
Experimental
Arm Description
Patient will go to the operating room (OR) first for irrigation and debridement with Irrisept (the experimental irrigation solution) and external fixation. Will return to OR at a later date for definitive fixation.
Arm Title
Antibiotic-coated medullary nail with saline irrigation (treatment group 2)
Arm Type
Experimental
Arm Description
Patient will go to the operating room (OR) for treatment with an antibiotic-coated nail and have irrigation and debridement with normal saline.
Arm Title
Antibiotic-coated medullary nail with Irrisept irrigation (treatment group 3)
Arm Type
Experimental
Arm Description
Patient will go to the operating room (OR) for treatment with an antibiotic-coated nail and have irrigation and debridement with Irrisept (the experimental irrigation solution).
Intervention Type
Drug
Intervention Name(s)
Irrisept (Irrigation Solution)
Intervention Description
Irrisept Antimicrobial Wound Lavage is intended for mechanical cleansing and removal of debris, dirt and foreign materials, including microorganisms from wounds.
Intervention Type
Drug
Intervention Name(s)
Saline
Intervention Description
Saline irrigation
Primary Outcome Measure Information:
Title
Rate of Surgical site infection (SSI)
Description
Rate of surgical site infection (SSI) and wound complications following surgery. Measured by the number of surgical site infections in the total population of patients in the cohort. Deep infection indicates return to the operating room. Superficial infection indicates local wound care and oral antibiotics.
Time Frame
90 days
Secondary Outcome Measure Information:
Title
Fracture Healing
Description
Presence or absence of fracture callous measured on x-ray by an experienced orthopaedic surgeon
Time Frame
6 months

10. Eligibility

Sex
All
Minimum Age & Unit of Time
18 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: Adult, 18 or over Gustilo-Anderson type III open tibia fracture Able to obtain informed consent from patient Exclusion Criteria: Minor, under 18 Pregnancy Prisoner Allergic to chlorhexidine gluconate Allergic to vancomycin or tobramycin Patient's tibia is unable to accommodate the smallest antibiotic nail Unable to provide informed consent
Central Contact Person:
First Name & Middle Initial & Last Name or Official Title & Degree
Stacee Baker, MEd BSN RN
Phone
573-884-9017
Email
bakersa@umsystem.edu
First Name & Middle Initial & Last Name or Official Title & Degree
Brett Crist, MD
Phone
573-882-6562
Email
cristb@umsystem.edu
Facility Information:
Facility Name
University of Missouri Health System
City
Columbia
State/Province
Missouri
ZIP/Postal Code
65212
Country
United States
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Stacee Baker, BSN, RN
Phone
573-884-9017
Email
bakersa@umsystem.edu

12. IPD Sharing Statement

Plan to Share IPD
No

Learn more about this trial

Irrisept Trauma Study

We'll reach out to this number within 24 hrs